Vanguard Asset Management
CRVS icon

Vanguard Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Vanguard Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$661K Buy
+44,219
New +$614K ﹤0.01% 2077

Other funds holding CRVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Asset Management's CRVS Position: Q2 2026 in Review

Vanguard Asset Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 44,219 shares worth $661K. The stake represents ﹤0.01% of the portfolio and ranks #2077 among its holdings.

160 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Vanguard Asset Management held 44,219 shares of Corvus Pharmaceuticals worth $661K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Vanguard Asset Management position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2077 holding.
  • 160 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.